Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Onodera, Y.
Right arrow Articles by Sato, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Onodera, Y.
Right arrow Articles by Sato, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 533-536
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae

Yoshikuni Onodera*, Yoko Uchida, Mayumi Tanaka and Kenichi Sato

New Product Research Laboratories I, Daiichi Pharmaceutical Co., Ltd, 16-13, Kitakasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan

The in-vitro inhibitory activities of sitafloxacin (DU-6859a) and other quinolones against Streptococcus pneumoniae DNA gyrase and topoisomerase IV were measured. IC50s of levofloxacin, ciprofloxacin, sparfloxacin and tosufloxacin against DNA gyrase were almost three to 12 times higher than those against topoisomerase IV. On the other hand, sitafloxacin showed dual inhibitory activity against both enzymes and its IC50s were the lowest among those of the quinolones tested. These results suggest that sitafloxacin is an effective agent against pneumococcal infections and that the incidence of drug-resistant mutants is low.

* Tel: +81-3-36890-0151; Fax: +81-3-5696-8344; E-mail: onode90j{at}daiichipharm.co.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
E. Cambau, S. Matrat, X.-S. Pan, R. Roth Dit Bettoni, C. Corbel, A. Aubry, C. Lascols, J.-Y. Driot, and L. M. Fisher
Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli
J. Antimicrob. Chemother., March 1, 2009; 63(3): 443 - 450.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Okumura, T. Hirata, Y. Onodera, K. Hoshino, T. Otani, and T. Yamamoto
Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae
J. Antimicrob. Chemother., July 1, 2008; 62(1): 98 - 104.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel
Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims
J. Antimicrob. Chemother., June 1, 2002; 49(6): 893 - 895.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. Yague, J. E. Morris, X.-S. Pan, K. A. Gould, and L. M. Fisher
Cleavable-Complex Formation by Wild-Type and Quinolone-Resistant Streptococcus pneumoniae Type II Topoisomerases Mediated by Gemifloxacin and Other Fluoroquinolones
Antimicrob. Agents Chemother., February 1, 2002; 46(2): 413 - 419.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. E. Morris, X.-S. Pan, and L. M. Fisher
Grepafloxacin, a Dimethyl Derivative of Ciprofloxacin, Acts Preferentially through Gyrase in Streptococcus pneumoniae: Role of the C-5 Group in Target Specificity
Antimicrob. Agents Chemother., February 1, 2002; 46(2): 582 - 585.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Takei, H. Fukuda, R. Kishii, and M. Hosaka
Target Preference of 15 Quinolones against Staphylococcus aureus, Based on Antibacterial Activities and Target Inhibition
Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3544 - 3547.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Fukuda, R. Kishii, M. Takei, and M. Hosaka
Contributions of the 8-Methoxy Group of Gatifloxacin to Resistance Selectivity, Target Preference, and Antibacterial Activity against Streptococcus pneumoniae
Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1649 - 1653.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
G. Ackermann, Y. J. Tang, A. C. Rodloff, J. Silva Jr, S. H. Cohen, and P. Heisig
In vitro activity of sitafloxacin against Clostridium difficile
J. Antimicrob. Chemother., May 1, 2001; 47(5): 722 - 724.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.